Presentation (CTI)

OBJECTIVES: The objective of this analysis was to evaluate the public drug plan listing status of innovative dermatology products available in Canada and to assess variation in coverage across jurisdictions following pan-Canadian Pharmaceutical Alliance (pCPA) negotiations.
METHODS: Dermatology products that received a recommendation from Canada's Drug Agency (CDA) or concluded with a pCPA Letter of Intent (LOI) between January 1 2016, and December 31 2025 were identified. For each product, CDA recommendation outcomes and dates, pCPA status, and public drug plan listing status were recorded. Listing status was assessed across provincial and federal drug plans using publicly available formularies and updated as of December 31 2025. A product was considered listed regardless of listing type or utilization criteria. Percentage of listing by jurisdiction was calculated for products with a signed pCPA LOI.
RESULTS: Twenty-three innovative dermatology products were identified during the study period. Indications included plaque psoriasis, atopic dermatitis, alopecia and acne. Among products with a signed pCPA LOI (n=16), listing rates across public drug plans ranged from 44% to 100%. While the national median listing rate was 94%, British Columbia listed only 44% (7/16) of products with a signed LOI. Manitoba, New Brunswick and Prince Edward Island had the next lowest listing rates at 88% (14/16). Several provinces demonstrated consistently high listing rates, whereas others showed delayed or limited adoption despite completed pCPA negotiations.
CONCLUSIONS: This analysis demonstrates that, although most innovative dermatology products that have successfully completed pCPA negotiations achieve public reimbursement in Canada, significant interprovincial disparities remain. British Columbia exhibits lower listing rates relative to the national median, resulting in unequal access to innovative dermatology therapies for patients across Canada.